Brainsway (BWAY) Set to Post Earnings on Tuesday

Key Points

• Brainsway is expected to report Q3 2026 results before the market opens on Tuesday, November 10. Analysts forecast earnings of $0.12 per share on revenue of $17.81 million.
• The company exceeded expectations in its prior quarter, posting $0.14 EPS versus the $0.10 consensus and $17.11 million in revenue versus the $16.54 million estimate.
• Despite shares trading at $11.19, analysts remain generally positive: five rate the stock a Buy and two rate it a Hold, resulting in a Moderate Buy consensus and an $18.20 average price target.

Brainsway (NASDAQ:BWAY - Get Free Report) is expected to issue its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect the company to post earnings of $0.12 per share and revenue of $17.81 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:00 AM ET.

Brainsway (NASDAQ:BWAY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. The company had revenue of $17.11 million during the quarter, compared to analysts' expectations of $16.54 million. Brainsway had a return on equity of 12.74% and a net margin of 15.65%. On average, analysts expect Brainsway to post $0.33 EPS for the current fiscal year and $0.57 EPS for the next fiscal year.

Brainsway Stock Up 0.9%

NASDAQ:BWAY traded up $0.10 on Tuesday, hitting $11.19. The stock had a trading volume of 20,941 shares, compared to its average volume of 147,005. The stock has a market cap of $450.20 million, a price-to-earnings ratio of 25.42 and a beta of 1.29. The business's 50-day simple moving average is $12.88 and its two-hundred day simple moving average is $13.93. Brainsway has a 52-week low of $7.14 and a 52-week high of $17.40.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on BWAY. HC Wainwright reiterated a "buy" rating on shares of Brainsway in a research note on Friday. BTIG Research restated a "buy" rating and set a $20.00 target price on shares of Brainsway in a research report on Thursday, September 10th. Wall Street Zen upgraded shares of Brainsway from a "hold" rating to a "buy" rating in a research report on Sunday, August 2nd. Weiss Ratings cut shares of Brainsway from a "hold (c+)" rating to a "hold (c)" rating in a report on Thursday. Finally, LADENBURG THALM/SH SH upped their target price on shares of Brainsway from $18.00 to $18.80 and gave the company a "buy" rating in a report on Thursday, August 13th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $18.20.

About Brainsway

BrainsWay Ltd. NASDAQ: BWAY is a medical technology company that develops and commercializes noninvasive therapies for brain disorders. Its core technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses a helmet-like device to deliver magnetic stimulation to targeted areas of the brain.

The company's Deep TMS systems are used in the treatment of major depressive disorder and obsessive-compulsive disorder, and have also received regulatory clearances for certain additional indications, including smoking cessation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.